Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the ...

American pharma giant Pfizer ($PFE) leads the pack as pharmaceutical companies plan price increases for at least 350 branded ...

This makes Pfizer a potentially cheap stock to buy while collecting a solid dividend. It's generated about $14 billion in ...

Pfizer’s shares, after a year of modest growth, recently fell following a cautious outlook for 2026, emphasizing ongoing ...

A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing ...

Let’s dive into details regarding each of the evaluated factors, but first, for quick context: With $143 Bil in market ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...

The drugmaker revised its revenue guidance for 2025, saying it now expects $62 billion in revenue for the year.

A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of ...

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company's common stock, payable March 6, 2026, to holders of the Common Stock of ...

The pharma giant announced that the Food and Drug Administration approved its new safety warning label for Depo-Provera — Pfizer’s birth control injection that has been a subject of controversy as ...

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click for this updated look at PFE stock.